Loading patent…
OwnerIgor Grachev, Sooin Hwang +4inventors
InventorsIgor Grachev, Sooin Hwang, Takahide Koda, Harald Murk, Takashi Nishida, Kousaku Ohinata
Estimating the term…
Peptides and pharmaceutically acceptable salts thereof and peptide conjugates and pharmaceutically acceptable salts thereof having 5 to 15 amino acids and having an amino acid sequence comprising at least 5 consecutive amino acids from the amino acid sequence LSSTQAQQSX1 (SEQ ID NO:1) for use in treating a subject suffering from or at risk of an inflammatory disease or disorder, schizophrenia or psychosis, a neurodegenerative disease such as Parkinson's disease. Alzheimer's disease, or ALS, a gastrointestinal disease or disorder such as irritable bowel syndrome, inflammatory bowel disease. Crohn's disease, or constipation, pain (e.g., visceral pain), rheumatoid arthritis, migraine, headache, substance abuse (e.g., substance use disorder such as drug use disorder, polysubstance use disorder, alcohol use disorder, or nicotine use disorder, tobacco use disorder), drug addiction, a seizure disorder, major depressive disorder, atypical depression, a major depressive episode (MDE) (e.g., atypical MDE), treatment resistant depression, depression in the presence of a neurodegenerative disease, cognitive impairment, COVID-19 related cognitive impairment and/or depression, ADHD, an autism spectrum disorder, a pervasive developmental disorder, atypical autism, multiple sclerosis, PTSD, a sleep disorder such as insomnia, daytime fatigue, or REM sleep behavior disorder, or for use in improving sleep in a subject.
A method of (a) treating a subject suffering from or at risk of schizophrenia or psychosis, an inflammatory disease or disorder, a neurodegenerative disease such as Parkinson's disease, Alzheimer's disease or ALS, a gastrointestinal disease or disorder such as irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, or constipation, pain (e.g., visceral pain), rheumatoid arthritis, migraine, headache, substance abuse (e.g., substance use disorder such as drug use disorder, polysubstance use disorder, alcohol use disorder, nicotine use disorder, or tobacco use disorder), drug addiction, a seizure disorder, major depressive disorder, atypical depression, a major depressive episode (MDE), treatment resistant depression, depression in the presence of a neurodegenerative disease, cognitive impairment, COVID-19 related cognitive impairment and/or depression, ADHD, an autism spectrum disorder, a pervasive developmental disorder, atypical autism, multiple sclerosis, PTSD, a sleep disorder such as insomnia, daytime fatigue, or REM sleep behavior disorder, (b) improving sleep in a subject, or (c) improving cognition in a subject, optionally wherein for (a)-(c) the subject has an elevated TNF-α level, comprising administering to the subject an effective amount of a peptide or a pharmaceutically acceptable salt thereof, wherein the peptide:
A method of (a) treating a subject suffering from or at risk of schizophrenia or psychosis, an inflammatory disease or disorder, a neurodegenerative disease such as Parkinson's disease, Alzheimer's disease, or ALS, a gastrointestinal disease or disorder such as irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, or constipation, pain (e.g., visceral pain), rheumatoid arthritis, migraine, headache, substance abuse (e.g., substance use disorder such as drug use disorder, polysubstance use disorder, alcohol use disorder, nicotine use disorder, or tobacco use disorder), drug addiction, a seizure disorder, major depressive disorder, atypical depression, a major depressive episode (MDE), treatment resistant depression, depression in the presence of a neurodegenerative disease, cognitive impairment, COVID-19 related cognitive impairment and/or depression, ADHD, an autism spectrum disorder, a pervasive developmental disorder, atypical autism, multiple sclerosis, PTSD, a sleep disorder such as insomnia, daytime fatigue, or REM sleep behavior disorder, (b) improving sleep in a subject, or (c) improving cognition in a subject, optionally wherein for (a)-(c) the subject has an elevated TNF-α level, comprising administering to the subject an effective amount of a peptide conjugate or a pharmaceutically acceptable salt thereof, wherein the peptide conjugate comprises a peptide moiety attached to a conjugate moiety, wherein the peptide moiety:
Dependencies are inferred from the claim text.